Claims
- 1. A compound having the (3R,S)- or (3R)-configuration of the formula: ##STR139## or a pharmaceutically acceptable acid addition salt thereof, wherein R.sup.1 is a group of the formula: ##STR140## where each Y, which is the same or different, is selected from hydrogen, halogen and C.sub.1 -C.sub.4 alkyl; and X is --(CH.sub.2).sub.2 --, --CH.dbd.CH--, --CH.sub.2 --S--, --CH.sub.2 O--, --S-- or --O--; and
- R is a group of the formula: ##STR141## where R.sup.2 and R.sup.3 are each independently hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxy-(C.sub.1 -C.sub.4 alkyl), hydroxy, C.sub.1 -C.sub.4 alkoxy, halogen, trifluoromethyl, nitro, cyano, sulphamoyl, --CO(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.4 alkyl), --CO.sub.2 (C.sub.1 -C.sub.4 alkyl), --(CH.sub.2).sub.n CONR.sup.6 R.sup.7, --(CH.sub.2).sub.n OCONR.sup.6 R.sup.7, --(CH.sub.2).sub.n NR.sup.8 R.sup.9 or --NHSO.sub.2 NH.sub.2, in which R.sup.6 and R.sup.7 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl, n is 0, 1 or 2, and R.sup.8 and R.sup.9 are independently hydrogen or C.sub.1 -C.sub.4 alkyl, or R.sup.8 is hydrogen and R.sup.9 is --SO.sub.2 (C.sub.1 -C.sub.4 alkyl), --CO(C.sub.1 -C.sub.4 alkyl) or --CONH(C.sub.1 -C.sub.4 alkyl), with the proviso that at least one of said R.sup.2 and R.sup.3 is always other than hydrogen or C.sub.1 -C.sub.4 alkyl; R.sup.4 is hydrogen, C.sub.1 -C.sub.4 alkyl or --CONH.sub.2 ; and R.sup.5 is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy.
- 2. A compound as claimed in claim 1 of the (3R,S)-configuration.
- 3. A compound as claimed in claim 1 of the (3R)-configuration.
- 4. A compound as claimed in claim 1 where each Y is the same.
- 5. A compound as claimed in claim 1 wherein R.sup.1 is a group selected from the group consisting of diphenylmethyl, di(4-fluorophenyl)methyl,1-(2-methylphenyl)-1-phenylmethyl, 1-(2-tert-butylphenyl)-1-phenylmethyl, (11H)-6,11-dihydrodibenzo[b,e]thiepin-11-yl, (5H)-10,11-dibenzyo[a,d]-cyclohepten-5-yl and (5H)dihydrodibenzo[a,d]cyclophepten-5-yl.
- 6. A compound as claimed in claim 5 wherein R.sup.1 is diphenylmethyl.
- 7. A compound as claimed in claim 1 wherein R is a group of the formula: ##STR142## wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each as previously defined in claim 1.
- 8. A compound as claimed in claim 7 where R.sup.2 and R.sup.3 in the definition of R are each independently hydrogen, methyl, ethyl, hydroxy-(C.sub.1 -C.sub.3 alkyl), hydroxy, methoxy, ethoxy, halogen, sulphamoyl, --CO(C.sub.1 -C.sub.2 alkyl), --OCO(C.sub.1 -C.sub.2 alkyl), --CONH.sub.2, --CONH(C.sub.1 -C.sub.2 alkyl), --OCONH(C.sub.1 -C.sub.2 alkyl), --NH.sub.2, --CH.sub.2 NH.sub.2, --CH.sub.2 NH(C.sub.1 -C.sub.2 alkyl), --NHSO.sub.2 (C.sub.1 -C.sub.2 alkyl), --NHCO(C.sub.1 -C.sub.2 alkyl), --CH.sub.2 NHCO(C.sub.1 -C.sub.2 alkyl), --CH.sub.2 NHCONH(C.sub.1 -C.sub.2 alkyl) or --NHSO.sub.2 NH.sub.2 ; R.sup.4 is hydrogen or --CONH.sub.2 ; and R.sup.5 is hydrogen.
- 9. A compound as claimed in claim 7 wherein R.sup.1 is diphenylmethyl.
- 10. A compound as claimed in claim 8 wherein R.sup.1 is diphenylmethyl.
- 11. A pharmaceutical composition useful for treating diseases associated with altered motility or smooth muscle tone or both, said composition comprising a pharmaceutically acceptable carrier or diluent and an anticholinergically-effective amount of a compound as claimed in claim 1.
- 12. A pharmaceutical composition useful for treating diseases associated with altered motility or smooth muscle tone or both, said composition comprising a pharmaceutically acceptable carrier or diluent and an anticholinergically-effective amount of a compound having the (3R,S)- or (3R)-configuration of the formula: ##STR143## or a pharmaceutically acceptable acid addition salt thereof, wherein R.sup.1 is a group of the formula: ##STR144## where each Y, which is the same or different, is selected from hydrogen, halogen and C.sub.1 -C.sub.4 alkyl; and X is --(CH.sub.2).sub.2 --, --CH.dbd.CH--, --CH.sub.2 --S--, --CH.sub.2 O--, --S-- or --O--; and
- R is a group of the formula: ##STR145## where R.sup.2 and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxy-(C.sub.1 -C.sub.4 alkyl), hydroxy, C.sub.1 -C.sub.4 alkoxy, halogen, trifluoromethyl, nitro, cyano, sulphamoyl, --CO(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.4 alkyl), --CO(C.sub.1 -C.sub.4 alkyl), --(CH.sub.2).sub.n CONR.sup.6 R.sup.7, --(CH.sub.2).sub.n OCONR.sup.6 R.sup.7, --(CH.sub.2).sub.n NR.sup.8 R.sup.9 or --NHSO.sub.2 NH.sub.2, in which R.sup.6 and R.sup.7 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl, n is 0, 1 or 2, and R.sup.8 and R.sup.9 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl, or R.sup.8 is hydrogen and R.sup.9 is --SO.sub.2 (C.sub.1 -C.sub.4 alkyl), --CO(C.sub.1 -C.sub.4 alkyl) or --CONH(C.sub.1 -C.sub.4 alkyl) R.sup.4 is hydrogen, C.sub.1 -C.sub. 4 alkyl or --CONH.sub.2 ; and R.sup.5 is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy.
- 13. A method for treating diseases associated with altered motility or smooth muscle tone or both in a mammal in need of such treatment, which comprises administering to said subject an anticholinergically-effective amount of a compound as claimed in claim 1.
- 14. The method as claimed in claim 13 wherein said mammal in need of treatment is afflicted with a disease selected from the group consisting of irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalascia and chronic obstructive airways disease.
- 15. A method for treating diseases associated with altered motility or smooth muscle tone or both in a mammal in need of such treatment, which comprises administering to said subject an anti-cholinergically effective amount of a compound having the (3R,S)- or (3R)- configuration of the formula: ##STR146## or a pharmaceutically acceptable acid addition salt thereof, wherein R.sup.1 is a group of the formula: ##STR147## where each Y, which is the same or different, is selected from hydrogen, halogen and C.sub.1 -C.sub.4 alkyl; and X is --(CH.sub.2).sub.2 --, --CH.dbd.CH--, --CH.sub.2 --S--, or --O--; and
- R is a group of the formula: ##STR148## where R.sup.2 and R.sup.3 are each independently hydrogen, C.sub.1 -C.sub.4 alkyl, hydroxy-(C.sub.1 -C.sub.4 alkyl), hydroxy, C.sub.1 -C.sub.4 alkoxy, halogen, trifluoromethyl, nitro, cyano, sulphamoyl, --CO(C.sub.1 -C.sub.4 alkyl), ---OCO(C.sub.1 -C.sub.4 alkyl), --CO.sub.2 (C.sub.1 -C.sub.4 alkyl), --(CH.sub.2).sub.n CONR.sup.6 R.sup.7, --(CH.sub.2).sub.n OCONR.sup.6 R.sup.7, --(CH.sub.2).sub.n NR.sup.8 R.sup.9 or --NHSO.sub.2, in which R.sup.6 and R.sup.7 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl, n is 0, 1 or 2, and R.sup.8 and R.sup.9 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl, or R.sup.8 is hydrogen and R.sup.9 is --SO.sub.2 (C.sub.1 -C.sub.4 alkyl), --CO(C.sub.1 -C.sub.4 alkyl) or --CONH(C.sub.1 -C.sub.4 alkyl); R.sup.4 is hydrogen, C.sub.1 - C.sub.4 alkyl or --CONH.sub.2 ; and R.sup.5 is hydrogen, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8816365 |
Jul 1988 |
GBX |
|
Parent Case Info
This is a continuation of application Ser. No. 07/376,263, filed Jul. 6, 1989, U.S. Pat. No. 5,089,505.
US Referenced Citations (10)
Foreign Referenced Citations (6)
Number |
Date |
Country |
0541598 |
May 1957 |
CAX |
0077607 |
Apr 1983 |
EPX |
1-13090 |
Jan 1989 |
JPX |
688345 |
Mar 1953 |
GBX |
780027 |
Jul 1957 |
GBX |
943603 |
Dec 1963 |
GBX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
376263 |
Jul 1989 |
|